Key result
Pretreating blood samples with deglycosylation enzymes improved diagnostic accuracy for heart failure and added prognostic value for mortality.
Why the study?
Does measurement of total NT-proBNP using deglycosylation enzymes improve diagnostic and prognostic accuracy compared to standard NT-proBNP in patients with acute dyspnea?
Observational (n=309)
Does measurement of total NT-proBNP using deglycosylation enzymes improve diagnostic and prognostic accuracy compared to standard NT-proBNP in patients with acute dyspnea?
Answers are grounded in this paper and cite their sources.
Pretreating blood samples with deglycosylation enzymes to measure total NT-proBNP improves diagnostic accuracy for heart failure and prognostic accuracy for mortality in patients with acute dyspnea.
BACKGROUND: The N-terminal part of pro-B-type natriuretic peptide (NT-proBNP) is glycosylated, but whether glycosylation influences the diagnostic and prognostic accuracy of NT-proBNP measurements is not known. METHODS: We measured NT-proBNP concentrations of 309 patients with acute dyspnea by use of standard EDTA tubes and EDTA tubes pretreated with deglycosylation enzymes. The primary cause of dyspnea was classified as heart failure (HF) or non-HF, and the diagnosis was adjudicated by 2 independent physicians. We collected information on all-cause mortality during follow-up. RESULTS: In all, 142 patients (46%) were diagnosed with HF. NT-proBNP concentrations in nondeglycosylated samples distinguished HF patients from patients with non-HF related dyspnea [median 3588 (quartiles 1-3 1578-8404) vs 360 (126-1139) ng/L, P < 0.001], but concentrations were markedly higher in samples pretreated with deglycosylation enzymes (total NT-proBNP) [7497 (3374-14 915) vs 798 (332-2296) ng/L, P < 0.001]. The AUC to separate HF patients from patients with non-HF related dyspnea was 0.871 (95% CI 0.829-0.907) for total NT-proBNP compared with 0.852 (0.807-0.890) for NT-proBNP measurements in standard EDTA plasma. During a median follow-up of 816 days, 112 patients (36%) died. Both NT-proBNP and total NT-proBNP concentrations were associated with mortality in separate multivariate models, but only total NT-proBNP concentrations provided added value to the basic risk model of our dataset as assessed by the net reclassification index: 0.24 (95% CI 0.003-0.384). There was a graded increase in risk across total NT-proBNP quartiles, in contrast with the results for NT-proBNP measurements. CONCLUSIONS: NT-proBNP concentrations were higher, and diagnostic and prognostic accuracy was improved, by pretreating tubes with deglycosylation enzymes.
No takes yet. Share an insight, caveat, or question.
Røsjø et al. (2015) conducted an observational in Acute dyspnea (n=309). Pretreatment of EDTA tubes with deglycosylation enzymes (total NT-proBNP) vs. Standard EDTA tubes (NT-proBNP) was evaluated on Diagnostic accuracy (AUC) to separate heart failure from non-heart failure related dyspnea (AUC 0.871, 95% CI 0.829-0.907). Pretreating blood samples with deglycosylation enzymes improved diagnostic accuracy for heart failure and added prognostic value for mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: